Overview

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
Phase:
N/A
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Melphalan
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate